ConcertAI named Casey Graves general manager of Clinical Solutions. In this role, Graves will drive growth and innovation in real-world data and AI solutions for oncology research and clinical care, accelerating advances that improve outcomes for patients and healthcare providers.
Deirdre Saulet was named chief strategy officer at Jasper Health.
When it comes to their survival, cancer cells have a host of backup plans.
Quest Diagnostics announced a pharmacogenomic laboratory test service designed to help providers understand the patient’s individual genetic response to select drug therapies.
Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.
The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation announced they will combine in a first-of-its-kind transaction in cancer philanthropy to launch the Samuel Waxman Institute for Aging & Cancer.
Top row (left to right): Dirk Görlich, Steven L. McKnight, Michael J. Welsh.Bottom row (left to right): Jesús (Tito) González, Paul A. Negulescu, Lucy ShapiroThe 2025 Albert Lasker Basic Medical Research Award honors went to two scientists for discoveries that exposed the structures and functions of low-complexity domains within protein sequences.
Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Pacdev (enfortumab vedotin), in combination with PD-1 inhibitor Keytruda (pembrolizumab), reached the main goals in a late-stage trial for certain patients with bladder cancer.
